In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Tricia Cottrell, MD, PhD, faculty for this educational event, received consulting fees from AstraZeneca.
Patrick Forde, MBBCH, faculty for this educational event, received research funding from AstraZeneca, BioNTech, BMS, Novartis, and Regeneron; and received consulting fees from Amgen, AstraZeneca, BMS, Daiichi, F-Star, G1, Genentech, Janssen, Iteos, Merck, Sanofi, Novartis, and Surface; and served on a Data & Safety Monitoring Board for Polaris.
Solange Peters, MD, PhD, faculty for this educational event, is principal investigator in trials sponsored by Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, and Roche/Genentech; and has received consulting fees from AbbVie, AiCME, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, Ipsen, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Peerview, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, and Vaccibody.
Jonathan D. Spicer, MD, PhD, FRCSC, faculty for this educational event, has received research funding from Merck (MSD), Roche, BMS, AZ,
Protalix Biotherapeutics, and CLS Therapeutics; and received consulting fees from Merck (MSD), BMS, AstraZeneca, Roche, Amgen, Chemocentryx, and Novartis.